CVS Health (NYSE: CVS) reported Q4 EPS of $1.92, $0.03 better than the analyst estimate of $1.89. Revenue for the quarter came in at $48.4 billion versus the consensus estimate of $47.54 billion.

Revenues in the Pharmacy Services Segment increased 9.3% to approximately $34.2 billion in the three months ended December 31, 2017. Same store sales increased 0.1% and pharmacy same store sales increased 0.4% in the three months ended December 31, 2017. Front store same store sales declined 0.7% in the three months ended December 31, 2017, and were positively impacted 80 basis points by seasonal cough and cold.

For the three months ended December 31, 2017, the generic dispensing rate increased approximately 80 basis points to 86.9% in our Pharmacy Services Segment and increased approximately 160 basis points to 86.8% in our Retail/LTC Segment, compared to the same quarter in the prior year.

2018 Guidance:

• At least $275 million of benefit from tax reform allocated to strategic investments in growth of our business, reducing adjusted operating profit growth by 250 basis points
• Updated full-year adjusted operating profit growth to down 1.5% to up 1.5%
• Provided first quarter adjusted operating profit growth of 0.5% to 4.5%

For earnings history and earnings-related data on CVS Health (CVS) click here.